GEN Exclusives

More »

GEN News Highlights

More »
Jun 9, 2010

Cellectis to Apply Its Meganuclease Technology to Engineer Lonza Cell Line

  • Lonza selected Cellectis bioresearch to help develop and commercialize a bioengineered cell line. Cellectis will use its meganuclease technology to deactivate the glutamine synthetase gene in Lonza’s host cell line CHOK1SV.

    Lonza’s GS System™ technology uses selection via glutamine metabolism to generate high-yielding, stable cell lines. The firm claims hundreds of cell lines using the GS System have already been created to generate therapeutic proteins for clinical trials and commercial supply.

    It maintains removal of the cell-based GS activity will enable further improvements to the selection process for creating recombinant cell lines. Cellectis specializes in the development of research tools for genome customization based on its meganuclease technology. Commercial products include its cGPS® System and cGPS Custom System kits for engineering specific cell lines.


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?